ANDA Approval and Patent Dispute Resolution

Amneal Pharmaceuticals (AMRX) received FDA ANDA 216213 approval for its generic version of lenalidomide, an immunomodulatory drug (IMiD) that targets the Cereblon E3 ubiquitin ligase complex, on February 19, 2025. This was made possible by a settlement of patent infringement litigation with Celgene, a subsidiary of Bristol Myers Squibb (BMS), the original developer. Through a strategic agreement between the two companies, Amneal secured a license to launch its generic product in the U.S. market without supply limitations, starting January 31, 2026. Resolving these regulatory and legal hurdles has provided Amneal with a crucial foothold for successfully establishing itself in the future U.S. hematological cancer market.

Reshaping the Blockbuster Revlimid Market

The original drug, Revlimid, is a key standard therapy for multiple myeloma and, as of 2021, was a global blockbuster drug with annual sales of approximately $12.8 billion. Following patent expiration and the entry of generics, BMS's Revlimid sales plummeted to approximately $6.1 billion in 2023, and market leadership is gradually shifting to more affordable generic products. Amneal's launch with unlimited supply rights is expected to further accelerate the erosion of the original drug's market share by driving large-scale prescription conversions. This can be seen as a typical example of disruptive innovation in the market following the patent cliff of a major branded product.

Cost Savings for Patients and Healthcare Systems

The full-scale launch of lenalidomide generics will provide significant cost savings for both multiple myeloma patients who have suffered from high cancer treatment costs and insurance companies facing financial pressures. Multiple myeloma and myelodysplastic syndromes, which are difficult-to-treat hematological malignancies, require long-term treatment, resulting in high drug costs. The availability of generic drugs that have undergone bioequivalence testing and demonstrated the same efficacy and safety as the original drug at a reasonable price will dramatically improve access to treatment. As a result, this will enhance the financial health of public and private insurance and improve the economic survival of patients, creating positive social value.

Intensifying Competition in the Generic Market

The U.S. lenalidomide generic market is currently dominated by strong global generic companies such as Teva Pharmaceuticals, Sandoz, Dr. Reddy's Laboratories, and Natco Pharma, all competing fiercely for market share. As a late entrant, Amneal is differentiating itself by emphasizing a stable supply chain and a diverse portfolio of capsule strengths (2.5mg, 5mg, 10mg, 15mg, 20mg, and 25mg), strengthening partnerships with hospitals and distributors. In particular, because this drug is teratogenic, it is strictly controlled under the Lenalidomide REMS program, so Amneal's ability to operate the REMS system will be a key factor in determining its initial market entry speed. The industry is watching to see how much of a first-mover advantage Amneal can maintain in the face of disruptive price competition for market share.